AgomAb Therapeutics NV (AGMB) vs TRex Bio (TRXB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
TRex Bio is the larger company by market cap ($297.0 million vs $268.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | TRXB |
|---|---|---|
| Share price | $5.45 | $10.32 |
| Market cap | $268.40M | $296.95M |
| 1-day change | -3.02% | +6.12% |
| EPS (TTM) | $-2.08 | $-2.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $16.56 |
| 52-week low | $5.39 | $9.06 |
| Distance from 52-week high | -69.42% | -37.71% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +591.19% | +183.57% |
| Average volume | 208.99K | 156.80K |
| Shares outstanding | 49.25M | 28.79M |
| Employees | 62 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About TRex Bio
TRXB stock →TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases in United States and Internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
AGMB vs TRXB FAQ
Which is bigger, AgomAb Therapeutics NV or TRex Bio?
TRex Bio (TRXB) is larger, with a market capitalization of $296.95M compared with $268.40M for AgomAb Therapeutics NV (AGMB).
Are AgomAb Therapeutics NV and TRex Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.